To demonstrate the absence of irritation potential (primary dermical irritability and cumulated dermical irritability) and allergy (sensibilization) of the product Dermacyd PHDETINLYN Sweet Flower...
Date First Received: November 4, 2008
Last Updated: November 4, 2008
Verified by: Sanofi-Aventis, November 2008
Clinical Trial Phase: Phase 3 | Start Date: July 2008
Overall Status: Completed
Estimated Enrollment: 53
Brief Summary
Official Title: “Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower”
Condition Keyword(s):
Intervention(s):
To demonstrate the absence of irritation potential (primary dermical irritability and cumulated dermical irritability) and allergy (sensibilization) of the product Dermacyd PHDETINLYN Sweet Flower.
Study Type: Interventional
Study Design: Supportive Care, Non-Randomized, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Study Primary Completion Date: September 2008
Intervention(s) in this Clinical Trial
- Drug: Dermacyd PH_DETINLYN (Lactic Acid)
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- Dermacyd PH_DETINLYN (Lactic Acid)
Outcome Measures for this Clinical Trial
Primary Measures
- The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research
Group (ICDRG) scale.
- Time Frame: Throughout the study
Safety Issue?: No
- Time Frame: Throughout the study
Criteria for Participation in this Clinical Trial
Inclusion criteria:
- Phototype Skin I,II, III e IV
- Integral skin test in the region;
- Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;
Exclusion criteria:
- Lactation or gestation
- Use of Antiinflammatory and/or immunossupression drugs
- Personnel history of atopy
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
- History of sensitivity or irritation for topic products;
- Active cutaneous disease;
- Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 60 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Sanofi-Aventis
Overall Clinical Trial Officials and Contacts
Jaderson Lima Study Director Sanofi-Aventis
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00785655
Study ID Number: LACAC_L_04299
ClinicalTrials.gov Identifier: NCT00785655
Health Authority: Brazil: National Health Surveillance Agency
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.